

# Hanns-Ulrich Marschall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123615/publications.pdf>

Version: 2024-02-01

215  
papers

23,550  
citations

11608

70  
h-index

8370

147  
g-index

223  
all docs

223  
docs citations

223  
times ranked

21204  
citing authors

#	ARTICLE	IF	CITATIONS
1	6 $\beta$ -hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice. <i>Gut</i> , 2023, 72, 314-324.	6.1	36
2	Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 405-423.	2.3	10
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
4	Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders. <i>Biochemical Society Transactions</i> , 2022, 50, 361-373.	1.6	16
5	Renal function after liver transplantation: Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus. <i>Digestive and Liver Disease</i> , 2022, 54, 1076-1083.	0.4	1
6	Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective. <i>Communications Biology</i> , 2022, 5, 379.	2.0	4
7	A Fatty Diet Induces a Jejunal Ketogenesis Which Inhibits Local SGLT1-Based Glucose Transport via an Acetylation Mechanism—Results from a Randomized Cross-Over Study between Iso-Caloric High-Fat versus High-Carbohydrate Diets in Healthy Volunteers. <i>Nutrients</i> , 2022, 14, 1961.	1.7	3
8	Recent advances on FXR-targeting therapeutics. <i>Molecular and Cellular Endocrinology</i> , 2022, 552, 111678.	1.6	27
9	Ring Trial on Quantitative Assessment of Bile Acids Reveals a Method- and Analyte-Specific Accuracy and Reproducibility. <i>Metabolites</i> , 2022, 12, 583.	1.3	5
10	Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage. <i>Journal of Lipid Research</i> , 2022, 63, 100238.	2.0	6
11	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	68
12	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 936-942.	1.4	37
13	Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: Potential importance of pathway intermediates. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 206, 105794.	1.2	12
14	Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. <i>Journal of Hepatology</i> , 2021, 74, 1087-1096.	1.8	38
15	A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the Turrific randomised trial. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 51.	0.9	21
16	Morbidity, risk of cancer and mortality in 3645 <i>hFE</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	1.9	11
17	STE20-type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. <i>Hepatology Communications</i> , 2021, 5, 1183-1200.	2.0	13
18	Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. <i>FASEB Journal</i> , 2021, 35, e21567.	0.2	15

#	ARTICLE	IF	CITATIONS
19	Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions. <i>Hepatology Communications</i> , 2021, 5, 1721-1736.	2.0	5
20	Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 547-558.	3.7	60
21	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. <i>Cell Metabolism</i> , 2021, 33, 1671-1684.e4.	7.2	165
22	The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURREFIC randomised trial. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1921-1929.	1.4	4
23	Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. <i>Nature Metabolism</i> , 2021, 3, 1228-1241.	5.1	65
24	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Diets—Data from a Randomized Cross-Over Study in Healthy Subjects. <i>Nutrients</i> , 2021, 13, 3322.	1.7	3
25	STE20-type kinase TAO3 regulates hepatic lipid partitioning. <i>Molecular Metabolism</i> , 2021, 54, 101353.	3.0	10
26	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
27	Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. <i>Journal of Lipid Research</i> , 2020, 61, 178-191.	2.0	23
28	Associations between Dietary Patterns and Bile Acids—Results from a Cross-Sectional Study in Vegans and Omnivores. <i>Nutrients</i> , 2020, 12, 47.	1.7	50
29	Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis. <i>Scientific Reports</i> , 2020, 10, 11523.	1.6	11
30	Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. <i>Liver International</i> , 2020, 40, 1366-1377.	1.9	14
31	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. <i>Scientific Reports</i> , 2020, 10, 3895.	1.6	27
32	Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G197-G211.	1.6	7
33	Ursodeoxycholic acid improves fetoplacental and offspring metabolic outcomes in hypercholanemic pregnancy. <i>Scientific Reports</i> , 2020, 10, 10361.	1.6	10
34	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. <i>Journal of Hepatology</i> , 2020, 72, 1122-1131.	1.8	47
35	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	2.4	18
36	The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against nonalcoholic fatty liver disease. <i>Molecular Systems Biology</i> , 2020, 16, e9495.	3.2	39

#	ARTICLE	IF	CITATIONS
37	Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease. <i>JCI Insight</i> , 2020, 5, .	2.3	14
38	Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. <i>Scientific Reports</i> , 2019, 9, 11525.	1.6	38
39	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	1.5	52
40	Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy. <i>Lancet, The</i> , 2019, 394, 810-812.	6.3	8
41	Muscle performance and fatigue in compensated chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 925-933.	0.6	6
42	Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E399-E410.	1.8	11
43	PS-159-Intestinal dysbiosis fuels liver disease progression via NLRP3 in the Mdr2 <sup>-/-</sup> mouse model of primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e100.	1.8	0
44	Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 1633-1640.	1.1	29
45	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. <i>Journal of Hepatology</i> , 2019, 71, 986-991.	1.8	44
46	Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans. <i>FASEB Journal</i> , 2019, 33, 9974-9989.	0.2	20
47	Reply. <i>Hepatology Communications</i> , 2019, 3, 848-848.	2.0	1
48	THU-007-Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through anti-inflammatory bile acid composition and signaling. <i>Journal of Hepatology</i> , 2019, 70, e163-e164.	1.8	1
49	Germline selection shapes human mitochondrial DNA diversity. <i>Science</i> , 2019, 364, .	6.0	178
50	Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis. <i>Hepatology</i> , 2019, 70, 276-293.	3.6	46
51	Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. <i>Gut</i> , 2019, 68, 1477-1492.	6.1	128
52	Gut pathobionts as triggers for liver diseases. <i>Nature Microbiology</i> , 2019, 4, 380-381.	5.9	1
53	Future Medical Treatment of PSC. <i>Current Hepatology Reports</i> , 2019, 18, 96-106.	0.4	6
54	Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. <i>Lancet, The</i> , 2019, 393, 899-909.	6.3	305

#	ARTICLE	IF	CITATIONS
55	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	1.4	15
56	Association of Adverse Perinatal Outcomes of Intrahepatic Cholestasis of Pregnancy With Biochemical Markers: Results of Aggregate and Individual Patient Data Meta-analyses. Obstetrical and Gynecological Survey, 2019, 74, 388-390.	0.2	6
57	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
58	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.2	34
59	Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 597-618.	2.3	32
60	A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data. Studies in Health Technology and Informatics, 2019, 260, 105-112.	0.2	1
61	Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form. Hepatology, 2018, 68, 787-787.	3.6	5
62	Colesevelam attenuates cholestatic liver and bile duct injury in <i>Mdr2</i> <sup>+/+</sup> mice by modulating composition, signalling and excretion of faecal bile acids. Gut, 2018, 67, 1683-1691.	6.1	53
63	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. Cell Metabolism, 2018, 27, 559-571.e5.	7.2	321
64	Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Scientific Reports, 2018, 8, 6658.	1.6	61
65	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. Hepatology, 2018, 68, 625-633.	3.6	20
66	High clinical impact and diagnostic accuracy of EUS-guided biopsy sampling of subepithelial lesions: a prospective, comparative study. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1304-1313.	1.3	33
67	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
68	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver International, 2018, 38, 523-531.	1.9	28
69	Role of Bile Acids in Metabolic Control. Trends in Endocrinology and Metabolism, 2018, 29, 31-41.	3.1	299
70	Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. Hepatology Communications, 2018, 2, 69-83.	2.0	35
71	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
72	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. Hepatology Communications, 2018, 2, 1299-1305.	2.0	56

#	ARTICLE	IF	CITATIONS
73	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. <i>Journal of Clinical Apheresis</i> , 2018, 33, 638-644.	0.7	12
74	STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1723-1737.	1.1	12
75	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2018, 155, 752-759.e5.	0.6	69
76	Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. <i>BMC Gastroenterology</i> , 2018, 18, 76.	0.8	28
77	Ensuring timely treatment of patients with primary biliary cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 591-593.	3.7	1
78	Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. <i>Frontiers in Pharmacology</i> , 2018, 9, 931.	1.6	56
79	The Importance of Gestation-Adjusted Birthweight Centile in Assessment of Fetal Growth in Metabolic Conditions. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2018, 10, 299-300.	0.4	0
80	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. <i>Gut</i> , 2017, 66, 611-619.	6.1	308
81	The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?. <i>Pharmacological Research</i> , 2017, 119, 20-26.	3.1	7
82	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
83	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. <i>Journal of Hepatology</i> , 2017, 67, 110-119.	1.8	44
84	Personal model-assisted identification of NAD <sup>+</sup> and Æglutathione metabolism as intervention target in NAFLD. <i>Molecular Systems Biology</i> , 2017, 13, 916.	3.2	147
85	Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling. <i>Digestive Diseases</i> , 2017, 35, 246-250.	0.8	80
86	Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. <i>Journal of Endocrinology</i> , 2017, 234, 15-27.	1.2	23
87	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
88	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	32
89	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1950-1956.e1.	2.4	84
90	Cyp3a11 is not essential for the formation of murine bile acids. <i>Biochemistry and Biophysics Reports</i> , 2017, 10, 70-75.	0.7	13

#	ARTICLE	IF	CITATIONS
91	Metabolic preconditioning protects BSEP/ABCB11 <sup>+/+</sup> mice against cholestatic liver injury. <i>Journal of Hepatology</i> , 2017, 66, 95-101.	1.8	51
92	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
93	Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. <i>Journal of Lipid Research</i> , 2017, 58, 412-419.	2.0	66
94	Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. <i>Current Hepatology Reports</i> , 2017, 16, 119-123.	0.4	12
95	Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis. <i>Journal of Molecular Medicine</i> , 2017, 95, 109-117.	1.7	21
96	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	0.6	60
97	Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis. <i>Medicine (United States)</i> , 2017, 96, e7708.	0.4	13
98	Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2017, 23, 3174.	1.4	4
99	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	3.6	101
100	Fibroblast growth factor 21 signaling: The liver in focus. <i>Hepatology</i> , 2016, 64, 333-335.	3.6	4
101	Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial. <i>Scientific Reports</i> , 2016, 6, 30173.	1.6	26
102	Could gut microbiota protect against sclerosing cholangitis?. <i>Hepatology</i> , 2016, 63, 26-27.	3.6	6
103	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. <i>Hepatology</i> , 2016, 63, 1287-1298.	3.6	85
104	746 Absence of BSEP/ABCB11 Protects From Cholestatic Liver Injury in Mice. <i>Gastroenterology</i> , 2016, 150, S1045.	0.6	0
105	Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. <i>Nature Genetics</i> , 2016, 48, 1396-1406.	9.4	533
106	Letter: ileal bile acid transporter inhibition- is there a potential for drug-drug interaction? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 751-751.	1.9	0
107	STK25 is a critical determinant in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2016, 30, 3628-3643.	0.2	41
108	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817

#	ARTICLE	IF	CITATIONS
109	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2016, 64, 674-681.	1.8	143
110	Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. <i>Cell Metabolism</i> , 2016, 24, 41-50.	7.2	1,734
111	The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 303-310.	1.9	74
112	Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 256-256.	0.6	2
113	Hepatocyte specific expression of an oncogenic variant of $\beta$ -catenin results in cholestatic liver disease. <i>Oncotarget</i> , 2016, 7, 86985-86998.	0.8	13
114	Variant adiponutrin confers genetic protection against cholestatic itch. <i>Scientific Reports</i> , 2015, 4, 6374.	1.6	6
115	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. <i>Journal of Hepatology</i> , 2015, 62, 1398-1404.	1.8	236
116	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
117	Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. <i>Journal of Hepatology</i> , 2015, 63, 456-461.	1.8	98
118	Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 189, 59-63.	0.5	80
119	Angiotensin II exerts dual actions on sodium-glucose transporter 1-mediated transport in the human jejunal mucosa. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1068-1075.	0.6	9
120	Management of intrahepatic cholestasis of pregnancy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1273-1279.	1.4	28
121	Reply. <i>Hepatology</i> , 2014, 60, 1452-1452.	3.6	0
122	A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy. <i>American Journal of Gastroenterology</i> , 2014, 109, 76-84.	0.2	103
123	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129
124	The Reversed Feto-Maternal Bile Acid Gradient in Intrahepatic Cholestasis of Pregnancy Is Corrected by Ursodeoxycholic Acid. <i>PLoS ONE</i> , 2014, 9, e83828.	1.1	84
125	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2013, 145, 574-582.e1.	0.6	795
126	Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1257-1264.	0.6	71



#	ARTICLE	IF	CITATIONS
127	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow band imaging: Impact of structured learning and experience on the accuracy of the Amsterdam classification system. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 160-167.	0.6	30
128	When Bile Acids Don't Get Amidated. <i>Gastroenterology</i> , 2013, 144, 870-873.	0.6	11
129	Risks of emergency cesarean section and fetal asphyxia after induction of labor in intrahepatic cholestasis of pregnancy: A hospital-based retrospective cohort study. <i>Sexual and Reproductive Healthcare</i> , 2013, 4, 17-22.	0.5	22
130	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . <i>Hepatology</i> , 2013, 58, 1074-1083.	3.6	150
131	Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 717-723.	1.1	200
132	Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: A population-based cohort study. <i>Hepatology</i> , 2013, 58, 1385-1391.	3.6	177
133	Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. <i>Cell Metabolism</i> , 2013, 17, 225-235.	7.2	1,671
134	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
135	Intrahepatic Cholestasis of Pregnancy and Associated Adverse Pregnancy and Fetal Outcomes. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 783-785.	0.2	0
136	Gallstone disease in Swedish twins is associated with the Gilbert variant of <i>UGT1A1</i> . <i>Liver International</i> , 2013, 33, 904-908.	1.9	10
137	Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. <i>Hepatology</i> , 2013, 57, 716-726.	3.6	146
138	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. <i>Journal of Hepatology</i> , 2012, 57, 366-375.	1.8	196
139	Stereological assessment of placental morphology in intrahepatic cholestasis of pregnancy. <i>Placenta</i> , 2012, 33, 914-918.	0.7	32
140	Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans. <i>Digestion</i> , 2012, 86, 244-249.	1.2	6
141	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow-band imaging: accuracy and interobserver agreement of different classification systems (with Tj ETQq1 1 0x784314 r3BT /Over		
142	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
143	Ursodeoxycholic Acid for Treatment of Fatty Liver Disease and Dyslipidemia in Morbidly Obese Patients. <i>Digestive Diseases</i> , 2011, 29, 117-118.	0.8	8
144	Nutritional Regulation of Bile Acid Metabolism Is Associated with Improved Pathological Characteristics of the Metabolic Syndrome. <i>Journal of Biological Chemistry</i> , 2011, 286, 28382-28395.	1.6	55

#	ARTICLE	IF	CITATIONS
145	Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1420-1423.	1.3	39
146	Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. <i>Hepatology</i> , 2010, 52, 197-203.	3.6	95
147	Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. <i>Journal of Internal Medicine</i> , 2010, 268, 279-285.	2.7	60
148	Inhibition of Na <sup>+</sup> -Taurocholate Co-transporting Polypeptide-mediated Bile Acid Transport by Cholestatic Sulfated Progesterone Metabolites. <i>Journal of Biological Chemistry</i> , 2010, 285, 16504-16512.	1.6	54
149	The genetic background of gallstone formation: An update. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 58-62.	1.0	34
150	Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. <i>Gut</i> , 2009, 58, 537-544.	6.1	179
151	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 <sup>-/-</sup> mice. <i>Hepatology</i> , 2009, 49, 1972-1981.	3.6	135
152	Fish protein hydrolysate elevates plasma bile acids and reduces visceral adipose tissue mass in rats. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 254-262.	1.2	98
153	Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. <i>Hepatology</i> , 2008, 47, 544-551.	3.6	102
154	Role of short-chain hydroxyacyl CoA dehydrogenases in SCHAD deficiency. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 6-11.	1.0	34
155	Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. <i>Gut</i> , 2007, 56, 265-270.	6.1	122
156	A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis. <i>American Journal of Pathology</i> , 2007, 171, 525-536.	1.9	293
157	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. <i>Molecular Pharmaceutics</i> , 2007, 4, 895-910.	2.3	22
158	Gallstone disease. <i>Journal of Internal Medicine</i> , 2007, 261, 529-542.	2.7	151
159	Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study. <i>Journal of Internal Medicine</i> , 2007, 262, 581-587.	2.7	49
160	Lithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice. <i>American Journal of Pathology</i> , 2006, 168, 410-422.	1.9	161
161	24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice. <i>Gastroenterology</i> , 2006, 130, 465-481.	0.6	282
162	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations. <i>Molecular Pharmaceutics</i> , 2006, 3, 231-251.	2.3	288

#	ARTICLE	IF	CITATIONS
163	Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. <i>Journal of Hepatology</i> , 2006, 44, 768-775.	1.8	158
164	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. <i>Journal of Hepatology</i> , 2006, 44, 243-245.	1.8	32
165	Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarbonyl reductase expressed in vascular endothelial tissue. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1205-1213.	2.4	42
166	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-1 $\pm$ /2 in the adaptive response to bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G923-G932.	1.6	154
167	Fxr $\alpha$ mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. <i>Journal of Lipid Research</i> , 2006, 47, 582-592.	2.0	98
168	Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease. <i>Transplantation</i> , 2006, 81, 1390-1397.	0.5	1,003
169	Chronic liver disease is triggered by taurine transporter knockout in the mouse. <i>FASEB Journal</i> , 2006, 20, 574-576.	0.2	106
170	Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. <i>World Journal of Gastroenterology</i> , 2006, 12, 7710.	1.4	27
171	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. <i>Transplant International</i> , 2005, 17, 804-9.	0.8	6
172	Genetic and environmental influences on symptomatic gallstone disease: A Swedish study of 43,141 twin pairs. <i>Hepatology</i> , 2005, 41, 1138-1143.	3.6	221
173	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. <i>Hepatology</i> , 2005, 42, 420-430.	3.6	295
174	Reply:. <i>Hepatology</i> , 2005, 42, 738-738.	3.6	4
175	Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. <i>Hepatology</i> , 2005, 42, 1399-1405.	3.6	226
176	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	268
177	Oncosis represents the main type of cell death in mouse models of cholestasis. <i>Journal of Hepatology</i> , 2005, 42, 378-385.	1.8	80
178	High-Dose Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: A 5-Year Multicenter, Randomized, Controlled Study. <i>Gastroenterology</i> , 2005, 129, 1464-1472.	0.6	343
179	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. <i>Transplant International</i> , 2004, 17, 804-809.	0.8	9
180	Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 481-487.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. <i>Hepatology</i> , 2004, 40, 467-474.	3.6	714
182	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , 2004, 127, 261-274.	0.6	525
183	Intrahepatic cholestasis of pregnancy. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 123-132.	0.3	42
184	Role of nuclear bile acid receptor, FXR, in determining ATP-binding cassette (ABC) transporter expression and cholestatic liver injury in common bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 124, A697-A698.	0.6	0
185	Basolateral hepatic export of bile acid glucuronides via MRP3: An important route for bile acid detoxification?. <i>Gastroenterology</i> , 2003, 124, A698.	0.6	1
186	Intrahepatic cholestasis of pregnancy: Identification of bile acid cut-off levels indicating fetal complications. <i>Gastroenterology</i> , 2003, 124, A786.	0.6	0
187	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 125, 825-838.	0.6	252
188	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 717-727.	1.8	260
189	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. <i>Journal of Hepatology</i> , 2003, 39, 480-488.	1.8	171
190	Expanded substrate screenings of human and Drosophila type 10 $\beta$ -hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: characterization of multifunctional $3\beta$ -HSD. <i>Biochemical Journal</i> , 2003, 376, 49-60.	1.7	87
191	Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F1281-F1289.	1.3	7
192	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangiocytes. <i>Gastroenterology</i> , 2002, 123, 1238-1251.	0.6	287
193	Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 44-52.	1.1	12
194	Primary cultures of human hepatocytes but not HepG2 hepatoblastoma cells are suitable for the study of glycosidic conjugation of bile acids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2001, 1530, 155-161.	1.2	5
195	Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. <i>Journal of Lipid Research</i> , 2001, 42, 735-742.	2.0	32
196	Cultured human hepatocytes but not HepG2 are suitable for the study of bile acid conjugation. <i>Gastroenterology</i> , 2000, 118, A999.	0.6	0
197	Human liver class I alcohol dehydrogenase $\beta$ isozyme: the sole cytosolic $3\beta$ -hydroxysteroid dehydrogenase of iso bile acids. <i>Hepatology</i> , 2000, 31, 990-996.	3.6	26
198	Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. <i>Journal of Hepatology</i> , 2000, 33, 1012-1021.	1.8	456

#	ARTICLE	IF	CITATIONS
199	Response. <i>Gastrointestinal Endoscopy</i> , 1999, 49, 818-819.	0.5	1
200	Bioinformatics in Studies of SDR and MDR Enzymes. <i>Advances in Experimental Medicine and Biology</i> , 1999, 463, 373-377.	0.8	7
201	Life-threatening complications of nasogastric administration of polyethylene glycol-electrolyte solutions (Golytely) for bowel cleansing. <i>Gastrointestinal Endoscopy</i> , 1998, 47, 408-410.	0.5	72
202	Long-Term Extracorporeal Bilirubin Elimination: A Case Report on Cascade Resin Plasmapheresis. <i>Blood Purification</i> , 1998, 16, 341-348.	0.9	13
203	Study of human isoursodeoxycholic acid metabolism. <i>Journal of Hepatology</i> , 1997, 26, 863-870.	1.8	17
204	Stimulation of bile acid 6 $\beta$ -hydroxylation by rifampin. <i>Journal of Hepatology</i> , 1996, 24, 713-718.	1.8	83
205	The influence of rifampin treatment on caffeine clearance in healthy man. <i>Journal of Hepatology</i> , 1995, 22, 78-81.	1.8	32
206	A new subgroup of lectin-bound biliary proteins binds to cholesterol crystals, modifies crystal morphology, and inhibits cholesterol crystallization. <i>Journal of Clinical Investigation</i> , 1995, 96, 3009-3015.	3.9	25
207	The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. <i>Hepatology</i> , 1994, 20, 845-853.	3.6	45
208	Portal Vein Thrombosis after Occlusion of a Transjugular Intrahepatic Portosystemic Shunt: Recanalization with the Impeller Catheter. <i>Journal of Vascular and Interventional Radiology</i> , 1994, 5, 467-471.	0.2	22
209	Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans. <i>Journal of Clinical Investigation</i> , 1992, 89, 1981-1987.	3.9	85
210	Synthesis of <sup>13</sup> C-labeled chenodeoxycholic, hyodeoxycholic, and ursodeoxycholic acids for the study of bile acid metabolism in liver disease. <i>Clinica Chimica Acta</i> , 1991, 203, 77-89.	0.5	9
211	Urinary excretion of bile acid glucosides and glucuronides in extrahepatic cholestasis. <i>Hepatology</i> , 1991, 13, 656-662.	3.6	32
212	Bile acid N-acetylglucosaminides. <i>FEBS Letters</i> , 1990, 270, 11-14.	1.3	15
213	Isolation of bile acid glucosides and N-acetylglucosaminides from human urine by ion-exchange chromatography and reversed-phase high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1988, 452, 459-468.	1.8	32
214	Evidence for bile acid glucosides as normal constituents in human urine. <i>FEBS Letters</i> , 1987, 213, 411-414.	1.3	45
215	6 $\beta$ -Glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes. <i>Lipids and Lipid Metabolism</i> , 1987, 921, 392-397.	2.6	35